Belite Bio (BLTE) Short-term Investments (2024 - 2025)
Belite Bio's quarterly Short-term Investments came in at $139.5 million in Q4 2025, up 28.06% year-on-year from $108.9 million in Q4 2024, and up 28.06% quarter-over-quarter from $108.9 million in Q4 2024.
Belite Bio has reported Short-term Investments for 2 years, with the latest figure at $139.5 million in Q4 2025.
- For the quarter ending Q4 2025, Short-term Investments rose 28.06% year-over-year to $139.5 million; the trailing twelve-month figure through Dec 2025 stood at $139.5 million (up 28.06% YoY), and the FY2025 full-year result was $139.5 million, up 28.06% from the prior year.
- Short-term Investments for Q4 2025 stood at $139.5 million, up from $108.9 million in the prior quarter.
- The five-year high for Short-term Investments was $139.5 million in Q4 2025, with the low at $108.9 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Belite Bio | 4.92 Bn | 4.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 139.49 Mn |
| Dec 31, 2024 | 108.92 Mn |